2-(异吲哚-1-基)乙酸 | 855292-39-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 2-(异吲哚-1-基)乙酸
• 中文别名: 1-异喹啉乙酸；异喹啉-1-乙酸
• 英文名称: 1-(carboxymethyl)isoquinoline
• 英文别名: isoquinolinyl acetic acid；Isoquinolineacetic acid；isoquinolinacetic acid；2-(Isoquinolin-1-YL)acetic acid；2-isoquinolin-1-ylacetic acid
• CAS: 855292-39-6
• 化学式: C₁₁H₉NO₂
• 分子量: 187.198
• InChiKey: CPPDVCCRUHPOSK-UHFFFAOYSA-N

物化性质

• 沸点：
  389.0±17.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(异吲哚-1-基)乙酸 在 甲酸铵 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 溶剂黄146 、 锌 、 sodium nitrite 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (RS)-N-benzyl 2-amino-2-(isoquinolin-1-yl)acetamide
  参考文献：
  名称：

  Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides

  摘要：

  N-Benzyl 2-acetamido-2-substituted acetamides, where the 2-substituent is a (hetero) aromatic moiety, are potent anticonvulsants. We report the synthesis and whole animal pharmacological evaluation of 16 analogues where the terminal 2-acetyl group was removed to give the corresponding primary amino acid derivatives (PAADs). Conversion to the PAAD structure led to a substantial drop in seizure protection in animal tests, demonstrating the importance of the N-acetyl moiety for anticonvulsant activity. However, several of the PAADs displayed notable pain-attenuating activities in a mouse model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.002
• 作为产物：
  描述：

  异喹啉-1-乙酸甲酯 在 水 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2-(异吲哚-1-基)乙酸
  参考文献：
  名称：

  Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides

  摘要：

  N-Benzyl 2-acetamido-2-substituted acetamides, where the 2-substituent is a (hetero) aromatic moiety, are potent anticonvulsants. We report the synthesis and whole animal pharmacological evaluation of 16 analogues where the terminal 2-acetyl group was removed to give the corresponding primary amino acid derivatives (PAADs). Conversion to the PAAD structure led to a substantial drop in seizure protection in animal tests, demonstrating the importance of the N-acetyl moiety for anticonvulsant activity. However, several of the PAADs displayed notable pain-attenuating activities in a mouse model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.002

文献信息

• Condensed heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0585913A2

  公开（公告）日：1994-03-09

  Novel compound represented by the formula: wherein ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR¹- (R¹ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS- or -C(R²)R2a- (R² and R2a independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR³- (R³ represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group , an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally substituted hydrocarbon group); ........ represents a single or double bond; when ........ is a single bond, Z represents -CR⁴- (R⁴ represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when ........ is a double bond, Z represents a carbon atom; D represents a C₁₋₃ alkylene group which may be substituted by an oxo group or a thioxo group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group; E represents -NR⁵- (R⁵ represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)n- (n is 0,1 or 2), or R⁵ and Y, taken together, may form a 5- to 7- membered ring which may be substituted by an oxo group or a thioxo group; G represents a bond or a C₁₋₃ alkylene group; Ar represents an optionally substituted aryl group or an optionally substituted heterocyclic group, provided that (1) when (i) -X-Y- represents - O-CO- or -CO-O-, (ii) D represents -CO- and (iii) E represents -NR⁵-, either (a) G represents a C₁₋₃ alkylene group and Ar represents a substituted aryl group or a substituted heterocyclic group, or (b) G represents a bond and R⁵ represents an optionally substituted hydrocarbon group, and (2) when -X-Y- represents -NH-CO-, D represents -CO-, or a salt thereof having an excellent activity of inhibiting ACAT, lowering chlesterol in blood and inhibiting tachykinin recepter, or a salt thereof, their production and use.

  由式表示的新型化合物： 其中环 A 可被取代 环 B 代表任选取代的苯环； X或Y代表-NR¹-（R¹代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基）、-O-或-S-，另一个代表-CO-、-CS-或-C(R²)R2a-（R²和R2a独立地代表氢原子或任选取代的烃基）、或 X 或 Y 代表-N=，另一个代表 =CR³-（R³ 代表氢原子、卤素原子、任选取代的烃基、任选取代的氨基、取代的羟基或被任选取代的烃基取代的巯基）； ........ 代表单键或双键； 当 ........ 为单键时，Z 代表-CR⁴-（R⁴ 代表氢原子、羟基或任选取代的烃基）或氮原子；或 (ii) 当 ........ 为双键时，Z 代表碳原子； D 代表可被氧代基团或硫代基团取代的 C₁₋₃亚烷基，或 D 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 元环； E 代表-NR⁵-（R⁵ 代表氢原子或任选取代的烃基）、-O-或-S(O)n-（n 为 0、1 或 2），或 R⁵ 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 分子环； G 代表键或 C₁₋₃ 亚烷基； Ar 代表任选取代的芳基或任选取代的杂环基，条件是 (1) 当(i)-X-Y-代表-O-CO-或-CO-O-，(ii)D 代表-CO-和(iii)E 代表-NR⁵-时， (a) G 代表 C₁₋₃亚烷基，Ar 代表取代的芳基或取代的杂环基、(2) 当-X-Y-代表-NH-CO-时，D代表-CO-，或其盐具有抑制 ACAT、降低血液中胆固醇和抑制速激肽受体的优异活性，或其盐的生产和使用。
• TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP0646112A1

  公开（公告）日：1995-04-05
• EP0646112A4
  申请人：——

  公开号：EP0646112A4

  公开（公告）日：1997-04-02
• SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES
  申请人：MERCK PATENT GmbH

  公开号：EP1133475A1

  公开（公告）日：2001-09-19
• COMPOUNDS FOR FLUORESCENCE IMAGING
  申请人：UNIVERSITE DE GENEVE

  公开号：EP2114462A2

  公开（公告）日：2009-11-11